Anx-A1 increases the strength of TCR signaling. (A) Electrophoretic mobility shift assay showing the effect of hrAnx-A1 on anti-CD3/CD28 (1.25μg/mL)–induced AP-1, NF-κB, and NFAT activation in T cells. Results are representative of 3 separate experiments with similar results. (B) Jurkat T cells were transfected with pAP-1-luc, pNF-κB-luc, and pNFAT-luc reporter constructs (3.0 μg) for 24 hours. Thereafter, cells were stimulated with the indicated concentrations of anti-CD3/CD28 in the presence or absence of hrAnx-A1 for 6 hours and then lysed to measure the luciferase activity. Values are the mean ± SE of 3 experiments in triplicate. **P < .01.